Drugs / universal CLL1 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07432100 | Feb 2026 → Dec 2028 expected | acute myeloid leukemia | Mingfeng Zhao | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | universal CLL1 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07432100 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T-cell (CAR-T cell) therapy is an adoptive immunotherapy” NCT07432100 ↗ |